GLYXAMBI 25MG/5MG 30 TAB

Glyxambi contains two active substances called empagliflozin and linagliptin. Each belongs to a group of medicines called “oral anti-diabetics”. These are medicines taken by mouth to treat type 2 diabetes. Glyxambi is added to metformin and/or sulphonylurea (SU) to treat type 2 diabetes in adult patients aged 18 years and older whose diabetes cannot be controlled when treated with metformin and/or sulphonylurea in combination with empagliflozin, or when treated with metformin and/or sulphonylurea in combination with linagliptin. Glyxambi can also be used as an alternative to taking both empagliflozin and linagliptin as single tablets. To avoid overdose, do not continue taking empagliflozin and linagliptin tablets separately if your are taking this medicine.